(Q33933071)

English

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database (English)

1 reference

Europe PubMed Central

30 July 2017

anti-retroviral agent

0 references

Reena Rajasuriar

object named as

Reena Rajasuriar

1

0 references

Sharon R. Lewin

object named as

Sharon R Lewin

9

0 references

object named as

Jennifer Hoy

5

0 references

6

object named as

Matthew Law

1 reference

Europe PubMed Central

30 July 2017

author name string

Maelenn Gouillou

2

1 reference

Europe PubMed Central

30 July 2017

Tim Spelman

3

1 reference

Europe PubMed Central

30 July 2017

Tim Read

4

1 reference

Europe PubMed Central

30 July 2017

Paul U Cameron

7

1 reference

Europe PubMed Central

30 July 2017

Kathy Petoumenos

8

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

2 June 2011

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

6

1 reference

Europe PubMed Central

30 July 2017

6

1 reference

Europe PubMed Central

30 July 2017

e20713

1 reference

Europe PubMed Central

30 July 2017

copyright license

Creative Commons Attribution 4.0 International

2 June 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Virologic and immunologic response to HAART, by age and regimen class

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients: association with HIV cellular viral load

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Hepatitis C and progression of HIV disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

5 July 2018

Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Comparison of CD4(+) T-cell subset distribution in chronically infected HIV(+) patients with various CD4 nadir counts.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Factors Influencing Increases in CD4 Cell Counts of HIV‐Positive Persons Receiving Long‐Term Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy

2 references

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107235

29 October 2018

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIV‐Infected Patients: Clinical Implications

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Age-related thymic activity in adults following chemotherapy-induced lymphopenia

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Changes in thymic function with age and during the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020713

21 January 2018

Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. The AVANTI and INCAS Study Groups

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rates of combination antiretroviral treatment change in Australia, 1997-2000

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21674057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0020713

1 reference

Europe PubMed Central

30 July 2017

2011PLoSO...620713R

0 references

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33933071&oldid=1869275593"